Aclaris Therapeutics, Inc. — Q2 2023 Form 10-Q Summary
Business Context and Reporting Period
Aclaris is a clinical-stage biopharmaceutical company developing therapies for immuno-inflammatory diseases and pursuing licensing, partnership, and other strategic transactions. The filing covers the quarter and six months ended June 30, 2023, with prior-period comparisons to June 30, 2022.
Key programs include zunsemetinib for rheumatoid and psoriatic arthritis, ATI-1777 for atopic dermatitis, ATI-2138 for ulcerative colitis and other T-cell-mediated diseases, and ATI-2231 for oncology-related indications. The company also operates a contract research laboratory-services segment.
Financial Highlights
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Total revenue | $1.9 million, versus $1.5 million | $4.4 million, versus $3.0 million |
| Operating loss | $31.8 million, versus $21.0 million | $61.7 million, versus $39.9 million |
| Net loss | $29.6 million, versus $20.5 million | $57.7 million, versus $39.3 million |
| Net loss per share | $0.42, versus $0.31 | $0.84, versus $0.62 |
| Net cash used in operating activities | Not separately presented | $47.0 million, versus $40.6 million |
- Six-month revenue increased $1.4 million, driven by a $2.2 million increase in licensing revenue, partly offset by a $0.7 million decrease in contract research revenue.
- Research and development expense increased to $47.9 million from $33.1 million, primarily reflecting higher zunsemetinib and ATI-2138 spending, personnel costs, and stock-based compensation.
- General and administrative expense increased to $17.1 million from $12.2 million, including $1.0 million of bad debt expense related to EPI Health.
- Other income increased to $4.0 million from $0.6 million, primarily because of higher interest income.
- The filing does not present a gross profit or gross margin because management does not consider gross profit meaningful at the company’s current revenue levels.
Cash, Liquidity, Capitalization, and Obligations
- At June 30, 2023, cash and cash equivalents were $31.2 million and marketable securities were $179.6 million, for total cash, cash equivalents, and marketable securities of approximately $210.8 million.
- Cash and cash equivalents declined from $45.3 million at December 31, 2022, primarily due to operating cash burn, partly offset by $26.7 million of net proceeds from an at-the-market equity offering.
- In April 2023, the company sold 3.4 million shares for $27.5 million of gross proceeds and $26.7 million of net proceeds after selling commissions and offering costs.
- The company reported no ongoing material financing commitments such as lines of credit or guarantees. The filing does not identify material outstanding debt.
- Contingent consideration related to the Confluence acquisition was $30.8 million at June 30, 2023, down from $33.1 million at December 31, 2022. Remaining potential milestone payments may total up to $75.0 million, in addition to potential royalties and other transaction-related payments.
- Existing cash, cash equivalents, and marketable securities are expected to fund operating and capital requirements for more than 12 months from issuance of the financial statements, although additional capital will be required to complete development programs and support discovery activities.
- Aggregate remaining lease obligations for existing spaces were $3.1 million. A new Wayne, Pennsylvania headquarters lease is expected to commence in November 2023 and carries total lease payments of $2.0 million over 64 months.
Material Changes Versus the Prior Comparable Period
- Revenue increased 47% for the six-month period, but operating loss increased 55% and net loss increased 47% because development and corporate expenses grew substantially faster than revenue.
- Contract research revenue declined 28% for the six months due to lower hours billed, partly offset by higher billing rates.
- Licensing revenue increased to $2.6 million from $0.5 million, primarily from royalties under the Eli Lilly agreement. Related licensing expense was $1.6 million.
- Research and development expense increased 45%; stock-based compensation included in total expenses increased to $13.3 million from $6.0 million.
- Net cash used in operations increased 16% to $47.0 million.
- The company issued approximately 4.1 million common shares during the first half of 2023, including the ATM issuance and shares issued upon equity award activity. Outstanding shares increased to 70.8 million at June 30, 2023 from 66.7 million at December 31, 2022.
- The authorized common stock limit was increased from 100 million to 200 million shares in June 2023.
Guidance, Outlook, Risks, and Unusual Items
- Management expects continued net losses and significant research and development spending for the foreseeable future.
- Expected clinical milestones include zunsemetinib rheumatoid arthritis topline data in the fourth quarter of 2023, ATI-1777 topline data in the second half of 2023, ATI-2138 data in September 2023, and zunsemetinib psoriatic arthritis topline data in the first half of 2024.
- The zunsemetinib hidradenitis suppurativa study failed to meet its primary and secondary efficacy endpoints, and the company will not pursue that indication further. This reduced the estimated contingent consideration liability.
- EPI Health filed for Chapter 11 bankruptcy on July 17, 2023. Aclaris recorded a $1.0 million allowance for doubtful accounts and corresponding bad debt expense for amounts due from EPI Health.
- The company states that it will require additional capital and may seek equity or debt financing, partnerships, royalties, milestones, or other strategic transactions. Additional financing may be unavailable or dilutive.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, inability to commercialize or partner drug candidates, dependence on third-party manufacturers, macroeconomic conditions, interest-rate and credit risks, and the possibility that cash resources will be insufficient if operating assumptions change.
- Marketable securities had $1.1 million of gross unrealized losses at June 30, 2023. Management does not expect a 10% immediate change in interest rates to materially affect the investment portfolio.
- No material legal proceedings were reported, and management stated that risk factors had not materially changed from the 2022 Form 10-K.
Investor Verification Checklist
- Verify the timing and results of the announced 2023 and 2024 clinical data readouts, particularly for zunsemetinib, ATI-1777, and ATI-2138.
- Monitor quarterly operating cash burn, marketable-security maturities, and the timing and terms of any additional financing.
- Assess the impact of EPI Health’s bankruptcy on royalty income, receivables, and potential milestone payments.
- Review the assumptions supporting the $30.8 million contingent consideration liability, including probability-of-success estimates and discount rates.
- Evaluate dilution from the ATM facility, equity awards, and the increased authorized share count.
- Confirm whether licensing, partnership, or strategic transactions generate meaningful non-dilutive funding.